BioSpace News Archive

Benvenue Medical, Inc., an innovative developer of minimally invasive surgery expandable implant solutions for lumbar fusions, announced that it has received U.S. Food and Drug Administration 510 clearance for the company’s enhanced Luna® XD MIS expandable interbody device.

Takeda Pharmaceutical Company Limited hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 with the U.S. Securities and Exchange Commission.

Esri, the global leader in geographic information systems (GIS), today announced that over 19,000 GIS professionals are expected to attend the 39th Annual Esri User Conference, to be held at the San Diego Convention Center from July 8-12.

ABN’s breakthrough stabilization technology platform holds promise for reducing cold chain reliance and improving access to life-saving vaccines

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR).

Approximately 10 million Americans age 50 and above have osteoporosis and another 44 million have low bone density, placing them at increased risk for bone fracture.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).

Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today the release of its 2018 Corporate Responsibility Report, which showcases the company’s progress on key initiatives to drive more sustainable operations, enhance product quality, build healthy communities, foster a strong work environment and improve access to healthcare.

Propanc Biopharma, Inc. (OTC: PPCBD) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that Propanc’s intellectual property (“IP”) portfolio has undergone rapid growth recently, with sixty-five patents currently either in force or pending in most major countries and regions around the world

Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing